Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 05:00 ET | Source: Promatix Biosciences, Ltd.

Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026

Promatix Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for ADCs
April 21, 2026 04:00 ET | Source: NTG Nordic Transport Group A/S

Transactions in connection with share buy-back program

Company announcement no. 11 - 2621 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...
April 21, 2026 02:11 ET | Source: Rinri Therapeutics Ltd.

Groundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 shows

Groundbreaking approaches such as cell therapies are on the horizon for transformation of neural hearing loss, a widespread but underdiagnosed condition.
April 21, 2026 02:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026

First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset...
April 21, 2026 01:00 ET | Source: Addex Therapeutics

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
April 20, 2026 17:00 ET | Source: Junshi Biosciences

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J
April 20, 2026 16:30 ET | Source: JATT II Acquisition Corp

JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering

WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of...
April 20, 2026 16:06 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are...
April 20, 2026 16:05 ET | Source: Equillium, Inc.

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today...
April 20, 2026 16:05 ET | Source: Abivax

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris &...